Tandem Diabetes Care (NASDAQ:TNDM) announces earnings results. Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) released its quarterly earnings results on Thursday. The medical device company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.15, FiscalAI reports. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%. The business had revenue of $283.69 million during the quarter, compared to analyst estimates of $265.85 million. During the same quarter in the prior year, the company posted ($0.31) EPS. Tandem Diabetes Care's quarterly revenue was up 13.8% compared to the same quarter last year. Here are the key takeaways from Tandem Diabetes Care's conference call: * Q3 results were strong: worldwide revenue rose 14% to $284 million and pump shipments increased 12%, while gross margin reached 57% and adjusted EBITDA margin was 6%. Tandem maintained its 2026 sales guidance of $1.065 billion-$1.085 billion. * Pharmacy adoption is progressing more slowly than expected, though formulary coverage reached about 50% and recurring supply economics exceeded baseline expectations. Tandem expects the transition to weigh on sales into 2027 and said mid- to high-single-digit revenue growth is a reasonable starting point for next year. * International sales rose 26% to a record $93 million, supported by product launches and stronger direct-market performance. Tandem plans to expand direct operations to cover roughly half of its international installed base by the end of 2027. * Product development could broaden Tandem's market opportunity: Mobi Tubeless is in late-stage FDA review, with commercial availability targeted for the first half of 2027 if cleared. The company also plans to begin a pivotal trial of its fully closed-loop system by year-end 2026, with a potential launch in 2028. Tandem Diabetes Care price performance. TNDM traded down $1.06 on Thursday, hitting $17.99. The company had a trading volume of 3,017,671 shares, compared to its average volume of 2,362,446. The stock has a fifty day simple moving average of $17.74 and a 200-day simple moving average of $18.90. The company has a debt-to-equity ratio of 4.62, a quick ratio of 2.65 and a current ratio of 3.18. Tandem Diabetes Care has a 52-week low of $12.26 and a 52-week high of $29.65. Here are the key news stories impacting Tandem Diabetes Care this week: * Third-quarter revenue rose 13.8% year over year to $283.7 million, topping analysts' expectations of $265.85 million. The adjusted loss of $0.10 per share was also narrower than the roughly $0.25-$0.27 loss forecast and the $0.31 loss a year earlier. Gross margin improved to 57%, up 2.7 percentage points year over year. These results point to improving growth and profitability trends. * Tandem projected 2026 sales of $1.065 billion to $1.085 billion. The range offers investors a revenue outlook, though the provided reports do not establish how it compares with market expectations. * The company named Jeannette Bankes as president and CEO as John Sheridan prepares to retire at the end of 2026. The planned succession provides a transition timeline, while investors may watch for details on leadership priorities and execution. * Despite the improvement, Tandem remained loss-making in the quarter. Sustaining revenue growth and margin gains while moving toward consistent profitability remains a key investor concern. Wall street analyst weigh in. Several equities analysts have recently issued reports on the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Tandem Diabetes Care in a research note on Tuesday, September 8th. UBS Group assumed coverage on Tandem Diabetes Care in a research note on Tuesday, July 28th. They issued a "neutral" rating and a $18.00 price target for the company. William Blair assumed coverage on shares of Tandem Diabetes Care in a report on Friday, August 21st. They issued an "outperform" rating on the stock. Canaccord Genuity Group set a $40.00 price target on shares of Tandem Diabetes Care in a report on Friday, August 7th. Finally, Truist Financial reduced their price objective on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a "buy" rating on the stock in a research report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $27.08. Insider buying and selling at Tandem Diabetes Care. In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the company's stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the transaction, the director owned 24,434 shares in the company, valued at approximately $467,911.10. This represents a 6.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.10% of the company's stock. Tandem Diabetes Care company profile. Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company's products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology. Tandem's product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software. Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

What Tandem Diabetes Care (TNDM) said on its Q3 earnings call. November 6, 2026 Key points. * Q3 revenue rose 14% to $284 million, with pump shipments up 12% and gross margin improving nearly three percentage points to 57%. Tandem reiterated its 2026 revenue outlook of $1.065 billion to $1.085 billion. * The shift to pharmacy distribution is progressing more slowly than expected, and its upfront-free PayGo model may weigh on revenue into 2027. CFO Leigh Vosseller called mid- to high-single-digit growth a "fair starting point" for 2027, not formal guidance. * International revenue climbed 26% to $93 million, while Tandem announced that Jeannette Bankes will succeed retiring CEO John Sheridan at year-end. The company also expects an FDA decision on its Mobi Tubeless system in Q4 and plans to begin a pivotal closed-loop study by the end of 2026. * Five stocks to consider instead of Tandem Diabetes Care. Tandem Diabetes Care NASDAQ: TNDM reported 14% revenue growth in the third quarter of 2026, as higher pump shipments, pharmacy pricing and international sales helped lift gross margin. The company also announced a CEO transition and signaled that a slower-than-expected shift to pharmacy distribution could weigh on revenue growth next year. Worldwide revenue rose to $284 million, while pump shipments increased 12% to approximately 33,000. Tandem reiterated its 2026 sales outlook of $1.065 billion to $1.085 billion. President and CEO John Sheridan plans to retire at the end of 2026. Jeannette Bankes will join Tandem on November 16 and become its next president and CEO, board Chair Beckie Robertson said. Sheridan said he would support Bankes through the transition. Pharmacy transition advances more gradually. U.S. sales rose 9% to $191 million, supported by pump demand, pharmacy pricing and adoption of Tandem's PayGo reimbursement model. U.S. pump shipments climbed 11% to nearly 23,000, and new customer starts returned to year-over-year growth. Chief Financial Officer Leigh Vosseller said approximately 70% of new customers converted from multiple daily insulin injections, while renewals grew at a double-digit rate. Pharmacy accounted for 15% of U.S. sales and approximately 12% of pump shipments in the quarter. Tandem reached about 50% formulary coverage among U.S. covered lives, meeting the high end of its year-end access target early. Even so, Vosseller said adoption has proceeded more gradually than initially anticipated, partly because healthcare providers, customers and Tandem's teams need time to establish new prescription workflows. She estimated that pharmacy would represent about 10% to 12% of both pump shipments and U.S. sales for the full year. Under PayGo, pumps carry no upfront charge, creating an initial revenue headwind that is offset over time by recurring supply sales. Vosseller said net monthly supply average selling prices were closer to $400, above the company's $350 baseline expectation, although she cautioned that the data covered only two quarters and relatively low volumes. For 2027, Vosseller said mid- to high-single-digit revenue growth was "a really fair starting point," rather than formal guidance. She noted that faster pharmacy adoption for pumps than for supplies could extend the transition's revenue headwind into next year. Tandem remains confident it can shift almost entirely to pharmacy, rather than durable medical equipment distribution, by the end of 2028, she said. International sales and margins improve. International revenue increased 26% to $93 million, or 27% in constant currency, with nearly 11,000 pumps shipped. Vosseller attributed the performance primarily to new product launches, direct-market execution and supply orders deferred from the second quarter. Discover more MarketBeat All Access MarketBeat Portfolio Tracker MarketBeat Research Tools Tandem began direct commercial operations in the U.K., Switzerland and Austria earlier in 2026 and said it was on track to launch in France during the week of the call. With France, the company expects to serve more than 30% of its international installed base directly, rising to approximately half by the end of 2027. Third-quarter gross margin improved nearly three percentage points from a year earlier to 57%, reflecting pricing benefits from the company's business model changes. Operating expenses rose 4% to $163 million, while adjusted EBITDA was 6% of sales, marking a fifth consecutive quarter of positive adjusted EBITDA. Tandem ended the quarter with $443 million in cash and investments. For 2026, Tandem continues to expect U.S. sales of $730 million to $745 million, international sales of $335 million to $340 million, gross margin of 56% to 57% and adjusted EBITDA margin of 5% to 6%. Product launches and closed-loop study ahead. Sheridan said Tandem believes its Mobi Tubeless system is in the late stages of U.S. Food and Drug Administration review and expects clearance in the fourth quarter. The product is designed to convert an existing rechargeable Mobi pump into a tubeless automated insulin delivery system using different supplies. Pending clearance, Tandem plans limited customer use followed by full commercial availability in the first half of 2027. Its initial submission focused on abdominal wear; Sheridan said the company is working with the FDA on additional wear locations and insulin types. Tandem also plans to begin a pivotal study of a fully closed-loop system based on the University of Virginia's AIDANET algorithm before the end of 2026. Sheridan said the study is expected to include more than 300 participants and potentially as many as 400, with data available for an FDA submission by the end of 2027. He said the company would expect the product to reach the market in 2028. The system is being designed to operate without meal announcements or other inputs while allowing users to make adjustments. Sheridan cautioned that Tandem has not specified whether an optional mealtime bolus will be part of the final feature set. About Tandem Diabetes Care (NASDAQ:TNDM). Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company's products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology. Tandem's product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Tandem Diabetes Care, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list. While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely. Continue following MarketBeat

Tandem Diabetes taps GE HealthCare exec Jeannette Bankes as CEO. Bankes will succeed John Sheridan, who plans to retire at the end of 2026. November 6, 2026 Associate Editor Tandem Diabetes Care has named Jeannette Bankes as its new president and chief executive officer (CEO). Bankes will take office on November 16. Bankes brings more than 30 years of global healthcare leadership experience, with a track record of turning strategy into growth and operational results. Her customer-focused approach and commitment to innovation align with Tandem's mission as the company advances its technology roadmap, expands access and pursues profitable growth. She has held senior leadership roles at several publicly traded healthcare companies, including GE HealthCare, Merck, Boston Scientific and Alcon. Her experience spans product management, marketing, sales, clinical and regulatory strategy, medical affairs, operations, and manufacturing. Most recently, Bankes served as president and CEO of GE HealthCare's $3.1 billion Patient Care Solutions segment, overseeing monitoring, diagnostic cardiology, maternal and infant care, and anesthesia businesses. Before that, she was senior VP and president of global franchises at Alcon, leading product development, portfolio management and commercialization across its surgical, vision care, and ocular health businesses. Bankes will succeed John Sheridan, who plans to retire at the end of 2026 following more than a decade with Tandem. Sheridan joined the company as COO in 2013 and became president and CEO in 2019. During his tenure, Tandem launched several automated insulin delivery systems, expanded its global operations and made changes to simplify access to its technology. He will remain with the company through the end of 2026 before transitioning to a consulting role to support the leadership handoff. In July, the company launched its t:slim X2 insulin pump compatibility with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor. Beckie Robertson, chair of Tandem's board: "On behalf of the Board, I thank John for his significant contributions and dedication to our customers, employees and shareholders. He established Tandem as a global leader in diabetes technology and positioned the Company for its next phase of growth. Jeannette is the right CEO to build on this foundation. Her broad operating experience, focus on the people we serve and ability to translate innovation into impact will be critical as we seek to deliver new technology and drive profitable growth." Bankes: "Tandem's compelling mission, differentiated portfolio and global reach create a meaningful opportunity to improve the lives of more people with diabetes. I am excited to work alongside the talented people at Tandem to build on these strengths, advance the innovation pipeline and expand access to our technology. Through disciplined execution and a continued focus on customers, we can extend Tandem's impact and deliver lasting value for the diabetes community and shareholders." Sheridan: "It has been a privilege to serve as Tandem's CEO and work alongside a dedicated organization united by our mission to improve the lives of people with diabetes, including half a million people worldwide who benefit from Tandem's technology. Jeannette is an exceptional leader, and I am confident that she and the Tandem team have the capability, passion and commitment to guide the Company into its next chapter." Add Mpo Mag as a preferred source on Google. Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.